Stephanie Jeansen1, Renger F Witkamp2, Jossie A Garthoff3, Ardy van Helvoort4, Philip C Calder5. 1. Danone Food Safety Centre, Palaiseau, France; Danone Research, 91767 Palaiseau Cedex, France. Electronic address: stephanie.jeansen@danone.com. 2. Wageningen University, Division of Human Nutrition, Wageningen, The Netherlands. 3. Danone Food Safety Centre, Palaiseau, France; Nutricia Research, Nutricia Advanced Medical Nutrition, Utrecht, The Netherlands. Electronic address: jossie.garthoff@danone.com. 4. Nutricia Research, Nutricia Advanced Medical Nutrition, Utrecht, The Netherlands; NUTRIM, School of Nutrition and Translational Research in Metabolism, Faculty of Health, Medicine, and Life Sciences, Maastricht University, The Netherlands. 5. Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton, Southampton, United Kingdom; National Institute for Health Research Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, University of Southampton, Southampton, United Kingdom.
Abstract
BACKGROUND & AIMS: The increased consumption of fish oil enriched-products exposes a wide diversity of people, including elderly and those with impaired health to relatively high amounts of n-3 long-chain polyunsaturated fatty acids (n-3 LC-PUFAs). There is an ongoing debate around the possible adverse effects of n-3 LC-PUFAs on bleeding risk, particularly relevant in people with a medical history of cardiovascular events or using antithrombotic drugs. METHODS: This analysis of 8 clinical intervention studies conducted with enteral medical nutrition products containing fish oil as a source of n-3 LC-PUFAs addresses the occurrence of bleeding-related adverse events and effects on key coagulation parameters (Prothrombin Time [PT], (activated) and Partial Thromboplastin Time [(a)PTT]). RESULTS: In all the patients considered (over 600 subjects treated with the active product in total), with moderate to severe disease, with or without concomitant use of antithrombotic agents, at home or in an Intensive Care Unit (ICU), no evidence of increased risk of bleeding with use of n-3 LC-PUFAs was observed. Furthermore there were no statistically significant changes from baseline in measured coagulation parameters. CONCLUSION: These findings further support the safe consumption of n-3 LC-PUFAs, even at short-term doses up to 10 g/day of eicosapentaenoic acid + docosahexaenoic acid (EPA + DHA) or consumed for up to 52 weeks above 1.5 g/day, in selected vulnerable and sensitive populations such as subjects with gastrointestinal cancer or patients in an ICU. We found no evidence to support any concern raised with regards to the application of n-3 LC-PUFAs and the potentially increased risk for the occurrence of adverse bleeding manifestations in these selected patient populations consuming fish oil enriched medical nutrition.
BACKGROUND & AIMS: The increased consumption of fish oil enriched-products exposes a wide diversity of people, including elderly and those with impaired health to relatively high amounts of n-3 long-chain polyunsaturated fatty acids (n-3 LC-PUFAs). There is an ongoing debate around the possible adverse effects of n-3 LC-PUFAs on bleeding risk, particularly relevant in people with a medical history of cardiovascular events or using antithrombotic drugs. METHODS: This analysis of 8 clinical intervention studies conducted with enteral medical nutrition products containing fish oil as a source of n-3 LC-PUFAs addresses the occurrence of bleeding-related adverse events and effects on key coagulation parameters (Prothrombin Time [PT], (activated) and Partial Thromboplastin Time [(a)PTT]). RESULTS: In all the patients considered (over 600 subjects treated with the active product in total), with moderate to severe disease, with or without concomitant use of antithrombotic agents, at home or in an Intensive Care Unit (ICU), no evidence of increased risk of bleeding with use of n-3 LC-PUFAs was observed. Furthermore there were no statistically significant changes from baseline in measured coagulation parameters. CONCLUSION: These findings further support the safe consumption of n-3 LC-PUFAs, even at short-term doses up to 10 g/day of eicosapentaenoic acid + docosahexaenoic acid (EPA + DHA) or consumed for up to 52 weeks above 1.5 g/day, in selected vulnerable and sensitive populations such as subjects with gastrointestinal cancer or patients in an ICU. We found no evidence to support any concern raised with regards to the application of n-3 LC-PUFAs and the potentially increased risk for the occurrence of adverse bleeding manifestations in these selected patient populations consuming fish oil enriched medical nutrition.
Authors: Beatriz Burger; Carolina M C Kühl; Thamiris Candreva; Renato da S Cardoso; Jéssica R Silva; Bianca G Castelucci; Sílvio R Consonni; Helena L Fisk; Philip C Calder; Marco Aurélio R Vinolo; Hosana G Rodrigues Journal: Sci Rep Date: 2019-06-24 Impact factor: 4.379
Authors: Paul C Norris; Ann C Skulas-Ray; Ian Riley; Chesney K Richter; Penny M Kris-Etherton; Gordon L Jensen; Charles N Serhan; Krishna Rao Maddipati Journal: Sci Rep Date: 2018-12-21 Impact factor: 4.379
Authors: Gibran Roder Feguri; Paulo Ruiz Lúcio de Lima; Anna Carolina Franco; Felipe Ramos Honorato De La Cruz; Danilo Cerqueira Borges; Laura Ramos Toledo; Neuber José Segri; José Eduardo de Aguilar-Nascimento Journal: Braz J Cardiovasc Surg Date: 2019 Mar-Apr